- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
BGB-16673 Is Safe, Highly Active Regardless of Baseline Mutations or High-Risk Features in R/R CLL/SLL
December 6th 2025, 6:48pm
ASH Annual Meeting and Exposition
In the CaDAnCe-101 study, BGB-16673 was tolerable, effective, and showed sustained disease control in high-risk, heavily pretreated, relapsed/refractory CLL/SLL.
Zanubrutinib Plus R-CHOP Is Active in Untreated DLBCL With Specific Gene Expression
December 6th 2025, 6:45pm
ASH Annual Meeting and Exposition
Zanubrutinib plus R-CHOP produced a high ORR and CR rate in untreated DLBCL with certain gene expression.
Families Face Financial Hardships in Pediatric ALL
December 6th 2025, 5:45pm
ASH Annual Meeting and Exposition
Thirty percent of families of pediatric patients with ALL receiving chemotherapy experienced catastrophic financial toxicities.
Early Use of Cilta-Cel Is Linked to Stronger Outcomes Due to Immune Fitness in R/R Myeloma
December 6th 2025, 5:44pm
ASH Annual Meeting and Exposition
Administering cilta-cel earlier in treatment improves clinical outcomes, with superior PFS and OS rates compared to later intervention.
Venetoclax-Based, Fixed-Duration Regimens Match Continuous Ibrutinib in Frontline CLL
December 6th 2025, 5:31pm
ASH Annual Meeting and Exposition
Fixed-duration venetoclax combinations delivered PFS comparable with continuous ibrutinib in the phase 3 CLL17 trial.
TBI-Free Conditioning Maintains Strong Outcomes in Pediatric and Young Adult B-Cell ALL
December 6th 2025, 5:19pm
ASH Annual Meeting and Exposition
The phase 2 EndRAD study found that removing TBI from conditioning did not compromise efficacy in pediatric or young adult patients with B-cell ALL.
Adjuvant Atezolizumab Generates DFS, OS Benefit Regardless of Tumor Size, Nodal Status, and Prior NAC in ctDNA+ MIBC
December 6th 2025, 4:19pm
Findings from an exploratory analysis of IMvigor011 support the use of serial ctDNA testing to guide atezolizumab use in MIBC.
Intravesical Cretostimogene Grenadenorepvec Is Active in BCG-Naive High-Risk NMIBC
December 6th 2025, 3:56pm
Intravesical cretostimogene grenadenorepvec was efficacious and safe in high-risk BCG-naive non–muscle-invasive bladder cancer.
Cretostimogene Grenadenorepvec Shows Efficacy in Papillary-Only, BCG-Unresponsive NMIBC
December 6th 2025, 4:01am
Cretostimogene grenadenorepvec shows durable activity in BCG-unresponsive papillary-only NMIBC with no progression to MIBC and favorable tolerability.
Gemcitabine Intravesical System Yields Low Rate of Radical Cystectomy in BCG-Unresponsive, High-Risk NMIBC
December 6th 2025, 2:00am
Gemcitabine intravesical system in BCG-unresponsive, high-risk NMIBC led to high CR rates and low radical cystectomy rates.
Experts Prepare for Several Key MCL Presentations at ASH 2025
December 5th 2025, 11:31pm
ASH Annual Meeting and Exposition
Hematology experts share the MCL abstracts they’re most looking forward to seeing at the 2025 ASH Annual Meeting.
Management of Peripheral Neuropathy Does Not Compromise Survival Benefit With Frontline Enfortumab Vedotin/Pembrolizumab in Urothelial Cancer
December 5th 2025, 9:22pm
Peripheral neuropathy was linked with improved efficacy outcomes after treatment with first-line enfortumab vedotin plus pembrolizumab in urothelial carcinoma.
Belzutifan Maintains High, Durable Responses in VHL Disease–Associated Neoplasms At 5 Years
December 5th 2025, 8:39pm
At 48 months, the majority of patients with VHL disease–associated tumors remained in response following treatment with belzutifan.
Dr George on Early Insights and Future Directions for Water Vapor Thermal Therapy in Prostate Cancer
December 5th 2025, 6:08pm
Arvin K. George, MD, discusses the mechanism of water vapor thermal therapy and the implications of VAPOR 2 findings in prostate cancer management.
Meta Analyses Show Suboptimal Efficacy With BCG in Metachronous NMIBC
December 5th 2025, 5:45pm
Those with metachronous NMIBC experienced poorer outcomes with BCG vs those with primary NMIBC.
Adjuvant Pembrolizumab Delivers Long-Term Benefits in ccRCC at Increased Risk of Recurrence
December 5th 2025, 2:00pm
Adjuvant pembrolizumab delivers sustained clinical benefits across ccRCC subgroups with no new long-term safety signals.
NDV-01 Elicits 92% CR Rate in High-Risk NMIBC
December 5th 2025, 1:00pm
Novel sustained-release NDV-01 achieved a 92% CR rate in high-risk patients with NMIBC with strong safety, supporting advancement to phase 3 studies.
Relief of Venous Congestion May Improve Renal Preservation Despite Worse Baseline Function in RCC With IVC Thrombosis
December 4th 2025, 8:18pm
Data from a comparative cohort study suggest that venous congestion is a modifiable driver of renal dysfunction in patients with RCC and IVC thrombosis.
Gemcitabine Intravesical System Use Is Practical and Straightforward in NMIBC
December 4th 2025, 7:51pm
Health care providers and allied health care professionals found the gemcitabine intravesical system straightforward to use and safe in NMIBC.
Experts Preview Anticipated HER2-Positive Breast Cancer Data Ahead of SABCS 2025
December 4th 2025, 1:00pm
San Antonio Breast Cancer Symposium
Leading experts highlight key HER2-positive studies ahead of SABCS 2025.